6533b825fe1ef96bd1281ec5
RESEARCH PRODUCT
Low dose of isotretinoin: A comprehensive review
Torello LottiRana AnadoluMrinal GuptaMohamed GoldustMohamed GoldustMohamed GoldustErhan AyhanMichelangelo VestitaMichelangelo VestitaBerat EbikAyman AbdelmaksoudDharmendra Dineshchandra Davesubject
Malemedicine.medical_specialtyNodulocystic acneDermatologyRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAcne VulgarismedicineHumansIsotretinoinskin and connective tissue diseasesAdverse effectIsotretinoinAcnebusiness.industryLow doseGeneral Medicinemedicine.diseaseDermatologyClinical PracticeSafety profileSearch terms030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugdescription
Isotretinoin is a first-generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti-inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date-unlimited PubMed search, from inception till December 2019, using the following search terms: "low-dose isotretinoin" and "dermatology," "isotretinoin and safety," "isotretinoin, off-label uses," "isotretinoin and male fertility," "isotretinoin, iPLEDGE system," aiming to deliver a therapeutic update relevant to clinical practice. All English-language articles were considered with no limitation based on the articles' type. Low-dose isotretinoin is not limited to old and novel dermatological conditions, but also showed promising results in the field of infertility and safety in the field of gastroenterology. We also highlight on the safety profile of the drug and experts' recommendations to enhance safety measures to decrease fetal risk while on isotretinoin.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-02-20 | Dermatologic Therapy |